Our History

Unmatched expertise in cell and gene therapies, beginning more than 30 years ago with the original cell therapy: stem cell transplantation

Contact our team to start building your solution

Powered by decades of experience and global cell collection network of the National Marrow Donor Program® (NMDP)/Be The Match®, Be The Match BioTherapies® partners with cell and gene therapy leaders to deliver high-quality, consistent and compliant therapies to more patients in need.

In collaboration with our research arm, the CIBMTR® (Center for International Blood and Marrow Transplant Research®), which has more than 45 years of experience collecting health outcomes data, our services support cellular therapies at every stage of development from clinical research through commercialization and long-term outcomes tracking.

Since inception, the NMDP/Be The Match and the CIBMTR have led the cellular therapy field through the management of:

A timeline of our history:

 

NMDP/Be The Match manages the first organizational donor search and bone marrow transplant, one year after its establishment as the United States’ national registry of volunteer bone marrow donors.

NMDP/Be The Match partners with the Medical College of Wisconsin to merge research operations into one leading global research program, officially known as the CIBMTR moving forward.

NMDP/Be The Match establishes Be The Match BioTherapies® as a natural extension of the mission to save lives through cellular therapy. Through this, Be The Match BioTherapies provides more than 30 years of expertise and proven solutions to companies developing new cell and gene therapies.

Be The Match BioTherapies executes contracts to provide cell sourcing and supply chain management services to power the development of allogeneic cell therapies.

 

Be The Match BioTherapies successfully collects and delivers first cellular therapy starting material for manufacture, less than 2 months after contract is signed.

 

Be The Match BioTherapies announces a collaboration with Magenta Therapeutics to expand the use of stem cell transplant to immune- and blood-based diseases.

 

MatchSource® software is launched for managing cell and gene therapy supply chains.

 

Be The Match BioTherapies begins U.S. and international apheresis center audits for commercial CAR-T Collection Network.

 

Be The Match BioTherapies invests in Tmunity Therapeutics to support the advancement of next-generation T cell immunotherapies.

 

Be The Match BioTherapies facilitates 100th cell collection.

 

 

Be The Match BioTherapies begins U.S. and international apheresis center network support for commercial CAR-T Collection Network.

 

Be The Match BioTherapies’ research partner, the CIBMTR, announces a collaboration with Kite to track long-term outcomes data for YESCARTA®.

 

Be The Match BioTherapies hosts the first annual Cell & Gene Therapy Standardization Summit, bringing together key industry stakeholders to discuss system capacity and needs and opportunities for standardization throughout the industry.

Be The Match BioTherapies launches efforts to establish international standards across the cell and gene therapy industry, prioritizing standardization in apheresis collections, supply chain logistics and outcomes data tracking.

 

Be The Match BioTherapies’ research partner, the CIBMTR, announces a collaboration with Novartis to track long-term outcomes data for Kymriah®.

 

Be The Match BioTherapies provides services to cell and gene therapy companies to support the development of 12 new innovative therapies.

 

Be The Match BioTherapies announces collaboration with National Health Service Blood and Transplant of the United Kingdom to provide more efficient access for cell and gene therapy developers to NHSBT’s authorized cell collection centers and close-to-patient cell manufacturing facilities in the U.K.

Be The Match BioTherapies launches the Quality System Audit Program to minimize collection infrastructure burden.

 

Be The Match BioTherapies and Gamida Cell launch strategic collaboration to support NiCord®, Gamida Cell’s investigational cell therapy.

 

Be The Match BioTherapies signs 20th biopharmaceutical client.

 

 

Be The Match BioTherapies announces collaboration with Poseida Therapeutics to support development of life-saving cellular therapies.

 

Be The Match BioTherapies announces strategic collaboration with Kiadis Pharma to support accelerate patient access to haploidentical stem cell therapies.